Anticoagulant Reversal Drugs Market By Drug Class (Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexmic Acid, Desmopressin, Idarucizumab, Andexxa) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Industry Outlook

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.

Market Synopsis

Anticoagulant Reversal Drugs Market

Get a sample copy for more information

"Recent Approval of First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market"

In May 2018, The U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing of anticoagulation effects. Andexxa received both orphan drug status and breakthrough designation by U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it to grow at fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drugs market owing to increased use of these agents during critical situation. Idarucizumab, approved in 2015 was the only drug for reversing the anticoagulation effects of dabigatran etexilate mesylate.

Anticoagulant Reversal Drugs Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Prothrombin Complex Concentrates (PCC)
 • Vitamin K
 • Protamine
 • Tranexmic Acid
 • Desmopressin
 • Idarucizumab
 • Andexxa
 • Pipeline Analysis
 • Phase III Drugs (Forecast till 2026)
   o Octaplex
 • Phase I and II Drugs (Tabular Representation)

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drugs market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.


Anticoagulant Reversal Drugs Market

Get a sample copy for more information

Key questions answered in this report

  • How the global anticoagulant reversal drugs market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the anticoagulant reversal drugs market and valuable opportunities for key players?
  • Who are the leading players in the global anticoagulant reversal drugs market?
  • Which is the leading and fastest region in the global anticoagulant reversal drugs market?
  • What are drivers and restrains governing the global anticoagulant reversal drugs market?
  • What is the pipeline of anticoagulant reversal drugs market?
Choose License Type
Published Date:  Mar 2019
Category:  Pharmaceuticals
Report ID:   59602
Report Format:   PDF
Pages:   120
Rating:    4.4 (66)
Connect With Us
+1-408-641-3282
24/7 Research Support